Improved T-cell function in CLL patients on BTK inhibitors is probably a result of the substantial reduction in disease burden, allowing the immune system to normalize. This effect is seen across different BTK inhibitors, challenging the older hypothesis that it was a specific off-target effect (ITK inhibition) of ibrutinib.
Current CAR-T therapy for CLL requires a complete response (CR) for long-term benefit. A partial response provides only about two years of disease control, an outcome similar to the oral drug pirtobrutinib but with significantly more toxicity, complexity, and logistical burden for the patient.
Despite its excellent tolerability, using pirtobrutinib in younger, treatment-naive CLL patients is cautioned against. The short follow-up data and the potential for unique resistance mutations could prevent the subsequent use of effective covalent BTK inhibitors, ultimately shortening the patient's overall treatment options.
The FLAIR trial provided the first clinical evidence that a time-limited combination of ibrutinib and venetoclax prevents the development of BTK resistance mutations. These mutations were observed in patients receiving continuous single-agent BTK inhibitor therapy, supporting a key theoretical advantage of time-limited combination approaches.
While second-generation BTK inhibitors are clinically similar, the next major advance in combination therapy may come from the BCL2 inhibitor component. The newer agent sonrotoclax is potentially more potent and selective than venetoclax, which could lead to superior efficacy and tolerability in future regimens.
BTK inhibitors block B-cell receptor signaling, causing long-surviving CLL cells to undergo programmed cell death (apoptosis) from a lack of stimulation. The common side effects are due to off-target kinase inhibition, not the intended BTK blockade itself, which has negligible action on other cells.
When a patient progresses on a covalent BTK inhibitor, using venetoclax next offers a strategic advantage beyond its efficacy. It may reshape the disease's clonal architecture by suppressing BTK-resistant clones, potentially restoring or improving the benefit from a different BTK inhibitor used later in the treatment course.
If a patient's CLL therapy is stopped for another major health issue, such as a second cancer, clinicians should often observe them post-recovery rather than immediately restarting treatment. This approach is recommended even with detectable Minimal Residual Disease (MRD) to prioritize the patient's immune system recovery and overall health.